220 related articles for article (PubMed ID: 28031572)
21. Development and Structural Modification of BACE1 Inhibitors.
Gu T; Wu WY; Dong ZX; Yu SP; Sun Y; Zhong Y; Lu YT; Li NG
Molecules; 2016 Dec; 22(1):. PubMed ID: 28025519
[TBL] [Abstract][Full Text] [Related]
22. Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity.
Han X; Jing Z; Wu W; Zou B; Peng Z; Ren P; Wikramanayake A; Lu Z; Leblanc RM
Nanoscale; 2017 Sep; 9(35):12862-12866. PubMed ID: 28850143
[TBL] [Abstract][Full Text] [Related]
23. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Probst G; Xu YZ
Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
[TBL] [Abstract][Full Text] [Related]
24. BACE1: from biomarker to Alzheimer's disease therapeutical target.
Cervellati C; Valacchi G; Zuliani G
Aging (Albany NY); 2021 May; 13(9):12299-12300. PubMed ID: 33982671
[No Abstract] [Full Text] [Related]
25. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors.
Zhou P; Li Y; Fan Y; Wang Z; Chopra R; Olland A; Hu Y; Magolda RL; Pangalos M; Reinhart PH; Turner MJ; Bard J; Malamas MS; Robichaud AJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2326-9. PubMed ID: 20202842
[TBL] [Abstract][Full Text] [Related]
26. Prolonged stability by cyclization: Macrocyclic phosphino dipeptide isostere inhibitors of beta-secretase (BACE1).
Huber T; Manzenrieder F; Kuttruff CA; Dorner-Ciossek C; Kessler H
Bioorg Med Chem Lett; 2009 Aug; 19(15):4427-31. PubMed ID: 19523824
[TBL] [Abstract][Full Text] [Related]
27. New evolutions in the BACE1 inhibitor field from 2014 to 2018.
Hsiao CC; Rombouts F; Gijsen HJM
Bioorg Med Chem Lett; 2019 Mar; 29(6):761-777. PubMed ID: 30709653
[TBL] [Abstract][Full Text] [Related]
28. In silico screening of potential β-secretase (BACE1) inhibitors from VIETHERB database.
Nhung NT; Duong N; Phung HTT; Vo QV; Tam NM
J Mol Model; 2022 Feb; 28(3):60. PubMed ID: 35156141
[TBL] [Abstract][Full Text] [Related]
29. BACE inhibitor bust in Alzheimer trial.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
[No Abstract] [Full Text] [Related]
30. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
31. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
Dotsenko VV; Chigorina EA; Krivokolysko SG
Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.
Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P
Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897
[TBL] [Abstract][Full Text] [Related]
33. Tarenflurbil: a shot on goal.
Aisen PS
Lancet Neurol; 2008 Jun; 7(6):468-9. PubMed ID: 18450518
[No Abstract] [Full Text] [Related]
34. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
[TBL] [Abstract][Full Text] [Related]
35. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
36. [Beta-secretase inhibitor].
Fukumoto H
Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():88-92. PubMed ID: 22755161
[No Abstract] [Full Text] [Related]
37. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
38. A practical entry to β-aryl-β-alkyl amino alcohols: application to the synthesis of a potent BACE1 inhibitor.
Delgado O; Monteagudo A; Van Gool M; Trabanco AA; Fustero S
Org Biomol Chem; 2012 Sep; 10(33):6758-66. PubMed ID: 22810961
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
Koriyama Y; Hori A; Ito H; Yonezawa S; Baba Y; Tanimoto N; Ueno T; Yamamoto S; Yamamoto T; Asada N; Morimoto K; Einaru S; Sakai K; Kanazu T; Matsuda A; Yamaguchi Y; Oguma T; Timmers M; Tritsmans L; Kusakabe KI; Kato A; Sakaguchi G
J Med Chem; 2021 Feb; 64(4):1873-1888. PubMed ID: 33588527
[TBL] [Abstract][Full Text] [Related]
40. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
Cully M
Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
